Neurogene to Participate in Stifel 2026 Virtual CNS Forum

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum.

Format: Management will participate in a fireside chat
Date: Wednesday, March 18 at 9:00 a.m. ET

A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the event will also be available for a limited time.

About Neurogene

Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311342818/en/

Company Contact:
Mike Devine
Executive Director, Corporate Communications
[email protected]

Investor Contact:
Argot Partners
[email protected]

Source: Neurogene Inc.

You May Also Be Interested In

• Roots Corporation Agrees to Go Private in Transaction Led by Marquee Brands, in Partnership with Canadian Retail Leaders Joseph Mimran and Frank Rocchetti, to Position Roots for Next Chapter of Global
• Grandmaster Tan Zhongyi Claims Second Cairns Cup Crown
• Coupa’s September Release Accelerates Agentic Spend Capabilities